To conduct a comprehensive analysis of radiologist-made assessments of glioblastoma (GBM) tumor size and composition by using a community-developed controlled terminology of magnetic resonance (MR) imaging visual features as they relate to genetic alterations, gene expression class, and patient survival.
Because all study patients had been previously deidentified by the Cancer Genome Atlas (TCGA), a publicly available data set that contains no linkage to patient identifiers and that is HIPAA compliant, no institutional review board approval was required. Presurgical MR images of 75 patients with GBM with genetic data in the TCGA portal were rated by three neuroradiologists for size, location, and tumor morphology by using a standardized feature set. Interrater agreements were analyzed by using the Krippendorff a statistic and intraclass correlation coefficient. Associations between survival, tumor size, and morphology were determined by using multivariate Cox regression models; associations between imaging features and genomics were studied by using the Fisher exact test.
Results:
Interrater analysis showed significant agreement in terms of contrast material enhancement, nonenhancement, necrosis, edema, and size variables. Contrast-enhanced tumor volume and longest axis length of tumor were strongly associated with poor survival (respectively, hazard ratio: 8.84, P = .0253, and hazard ratio: 1.02, P = .00973), even after adjusting for Karnofsky performance score (P = .0208). Proneural class GBM had significantly lower levels of contrast enhancement (P = .02) than other subtypes, while mesenchymal GBM showed lower levels of nonenhanced tumor (P , .01).
Conclusion:
This analysis demonstrates a method for consistent image feature annotation capable of reproducibly characterizing brain tumors; this study shows that radiologists' estimations of macroscopic imaging features can be combined with genetic alterations and gene expression subtypes to provide deeper insight to the underlying biologic properties of GBM subsets.
NEURORADIOLOGY: MR Imaging Predictors of Molecular Profile and Survival Gutman et al developed to normalize grading of visual/subjective MR imaging features of malignant gliomas (10). The feature set was developed by domain experts (ie, neuroradiologists) to include the majority of possible subjective MR imaging features associated with malignant primary brain tumors with a validated grading system to rate each feature. It was built on many of the observations that have been previously tested and validated in the imaging literature (5) . The 30 distinct features and corresponding criteria of the VASARI were developed and validated based on a consensus opinion of a panel of eight neuroradiologists at multiple institutions with extensive experience in neuro-oncology. They are based on four cardinal imaging features of nonenhanced tumor, contrast-enhanced tumor, necrosis, and edema. Terms were grouped into general categories such as lesion location, morphology, margin, vicinity of lesion, and remote alterations. The observations were harmonized against ontologies such as contrast enhancement (5) (6) (7) (8) . However, since these studies do not use consistent imaging feature descriptors, the results are difficult to compare. In addition to prognostic information, MR imaging features may also serve as noninvasive biomarkers that could offer insight to underlying molecular pathways. A comprehensive imaging-genomic analysis performed by using quantitative MR imaging volumetrics and large-scale genetic and micro-RNA expression profiles recently demonstrated the potential for molecular subtyping based on signal intensity on fluid-attenuated inversion recovery (FLAIR) images (9) .
To uncover meaningful correlations between imaging features and genomic aberrations, it is critical to measure MR features both accurately and reproducibly. Since qualitative analysis of clinical neuroimaging can be obfuscated by a lack of reproducible and validated objective measures, our study utilized a subset of a recently developed controlled terminology that incorporates the majority of the visible subjective MR imaging features associated with malignant primary brain tumors. This comprehensive feature set schema (known as VASARI, for Visually AcceS-Able Rembrandt Images; https://wiki .nci.nih.gov/display/CIP/VASARI) was G lioblastoma (GBM) is a malignant primary brain tumor with a poor prognosis (median survival, 14 months) despite aggressive multimodal therapy (1-3). GBM's heterogeneous neuroimaging, pathologic, and molecular features provide opportunities for subclassification, prognostication, and the development of targeted therapies (4) . Noninvasive methods for diagnosing, subtyping, and monitoring growth or response to therapy would advance the practice of neuro-oncology. While the current role of magnetic resonance (MR) imaging has been limited to establishing the initial diagnosis and to monitoring treatment response, MR imaging also has the capability of quantifying specific phenotypic imaging features of these tumors, such as the volume of the necrotic core or surrounding contrast material-enhanced rim. This suggests that capturing the imaging characteristics of GBM could provide additional parameters for cataloging these tumors.
Several imaging features have been shown to have potential prognostic value. Previous studies have modeled overall survival by using feature combinations that include preoperative tumor volume, Karnofsky performance status (KPS), involvement of eloquent brain regions, volume of the nonenhanced tumor, extent of edema, extent of resection, degree of necrosis, and degree of Implications for Patient Care n The combination of standardized neuroimaging, pathologic, and genomic features may provide a more precise method to predict a GBM tumor's biologic behavior and be used to better predict individual patient survival.
n Refinements in the classification of GBM tumors through imaging phenotype characterization may help individualize treatment regimens for this disease.
n As volumetric assessment of GBM tumor composition is not widely available, these data suggest radiologist review of MR imaging data has adequate prognostic value and correlates with genomic biomarkers.
Advances in Knowledge
n Semiquantitative assessment of glioblastoma (GBM) compartments on MR images (eg, necrosis, contrast material enhancement, edema) on the basis of a standardized feature set is predictive of overall survival.
n Molecularly defined tumor subtypes show observable differences in macroscopic appearance: Proneural tumors were associated with low levels of contrast enhancement, and mesenchymal tumors were associated with lower degrees of nonenhanced tumor relative to other subtypes.
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does not enhance or that showed absence of central enhancement with corresponding increased signal intensity on T2-weighted and proton density-weighted images. Edema was defined on FLAIR or T2-weighted images with signal intensity greater than that of nonenhanced tumor but lower than that of cerebrospinal fluid. A lesion size estimate was also used, which was measured as the two largest perpendicular cross-sectional diameters of T2weighted signal intensity abnormality on a single axial image (Fig 1) . For each patient image set, the feature assessments for each tumor from each of the three neuroradiologists were collapsed into a single set consisting of a consensus value for each of the imaging features. For the ordinal tumor composition features (proportion contrast-enhanced tumor, proportion nonenhanced tumor, proportion necrosis, and proportion edema), the consensus value was equal to the category the neuroradiologists selected most frequently. Missing measurements for a particular imaging feature were ignored in the determination of the consensus value. For the quantitative lesion size measurements, the consensus value was equal to the median of the neuroradiologists' measurements.
Interreader Agreement
We assessed the interreader agreement of each of the tumor compartment features by using the Krippendorff a statistic (17) . Values close to 1 indicate high interreader agreement for that particular feature, whereas values close to 0 indicate that agreement in any two readers' measurements of that feature for the same patient is due to chance. A Krippendorff a value less than zero indicates that interreader disagreements are systematic.
Interreader agreement for the lesion size measurements was assessed by means of the intraclass correlation coefficient. The intraclass correlation coefficient of the square roots of the lesion length feature values were computed since the square root transformations made these quantities approximately normally distributed.
images obtained before and after contrast material administration) were eliminated (n = 5) leaving a total of 75 cases for analysis. All available images, as of November 2011, on the Cancer Imaging Archive portal were included in the initial analysis. Cases were reviewed between February and November 2011.
For each patient, three board-certified neuroradiologists independently reviewed axial T1-weighted MR images before and after gadolinium-based contrast material administration as well as axial T2-weighted FLAIR images. Images were viewed on a workstation (ClearCanvas, Toronto, Canada; http:// clearcanvas.com) with an electronic case report form installed that implemented the VASARI feature set for human GBM (12) (13) (14) (15) (16) . For the purposes of this study, the four cardinal VASARI MR imaging features were used, plus a single measure of lesion size. This subset was chosen based on the consistent representation across patients and on the ease of segmentation. The four cardinal variables were the percentage of total abnormal tissue classified as contras-enhanced tumor, nonenhanced tumor, necrosis, and edema. These variables were visually estimated by neuroradiologists and then divided into categories (eg, 0%-5%, 6%-33%, 34%-67%, 68-95, 95%-100%) according to the VASARI guidelines. Contrast-enhanced tumor was defined as that with increased signal intensity on T1-weighted images compared with that on precontrast images. Nonenhanced tumor was defined as regions of T2-weighted image hyperintensity (less than the signal intensity of cerebrospinal fluid and edema, with corresponding T1-weighted hypointensity) that is associated with mass effect and architectural distortion, including blurring of the gray-white interface. Necrosis was defined as a region within the tumor with irregular margins that RadLex ® to ensure interoperability. By using specific guidelines and controlled vocabulary, the feature set is designed to comprehensively describe the tumor in consistent and reproducible terms. This work also demonstrates that radiologist-made measurements of these features are reproducible, clinically meaningful, and biologically relevant.
The purpose of this study was to conduct a comprehensive analysis of radiologist-made assessments of GBM tumor size and composition by using a community-developed controlled terminology of MR imaging visual features as they relate to genetic alterations, gene expression class, and patient survival.
Materials and Methods

Radiologic Annotation and Mark-up Process
Because patient-derived clinical, imaging, and genomic data has been previously deidentified by the Cancer Genome Atlas (TCGA), which is a publicly available data set that contains no linkage to patient identifiers, no institutional review board or Health Insurance Portability and Accountability Act approval was required for our study. Baseline MR imaging data sets for 88 GBM patients with complete survival data ( We then investigated whether any imaging features we found to be associated with overall survival in the analysis above were still associated after adjusting for standard clinical variables, including those that have previously been shown to be correlated with survival, such as KPS, age, and sex. We first performed a stepwise variable selection among the clinical variables to determine which to include in the Cox regression model. Twenty-three of the 68 patients for whom overall survival was available had missing KPS values. For all of these patients, we imputed KPS values of 80, the most commonly occurring KPS value in the data set; analyses indicated that this approach outperformed more complicated multiple imputation procedures. We then performed another stepwise variable selection among the imaging features to determine which to add to this model. We next tested the association between overall survival and any imaging features we selected in the above analysis after adjusting for the standard clinical variables by performing a likelihood ratio test of the clinical
Survival and Association Analysis
Survival data representing time between initial diagnosis and death were downloaded directly from the TCGA data portal (http://tcga-data.nci.nih .gov/tcga/tcgaHome2.jsp). The relationship between survival, mutation status, or molecular subtype and imaging features was addressed separately by type of image. All analyses were conducted by using either custom-written code in Matlab (Mathworks, Natick, Mass) or SAS (SAS, Cary, NC).
We examined the association between these imaging features and overall survival through Cox regression, using stepwise variable selection to determine which features to include in the model. For the purpose of this analysis, we coded the assigned ranges of values from the radiologists of each of these features as the range midpoint; we coded 0%-5% as 0.025, 6%-33% as 0.195, 34%-67% as 0.505, and so on. Seven of the 75 patients were missing overall survival outcomes; we did not use data for these patients for this analysis. 
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Neuroimaging Features and Survival
The length of the lesion's major axis, based on the longest axis section at T2-weighted FLAIR imaging, and the proportion of contrast-enhanced tumor were both significantly associated with poor survival (hazard ratio: 1.02, P = .00973, and 8.84, P = .0253, respectively) (Fig 2) . Overall survival was not significantly associated with the proportion of necrosis, proportion of edema, proportion of nonenhanced tumor, or length of the lesion's minor axis.
Of the three standard clinical variables we considered, only KPS was associated with overall survival (hazard ratio: 0.972, P = .0057; Table 1 ). Even when KPS was included in the Cox regression model, the length of the lesion's
Results
Interrater Reliability
Interreader agreements for the four cardinal imaging features were moderate to high; the tumor composition feature with the highest interreader agreement was proportion contrast-enhanced tumor (a = 0.607; 95% confidence interval [CI]: 0.403, 0.749). Moderate agreements were also noted for the other estimates: proportion nonenhanced tumor (a = 0.428; 95% CI: 0.239, 0.565), proportion necrosis (a = 0.511; 95% CI: 0.358, 0.646), and proportion edema (a = 0.496; 95% CI: 0.339, 0.608). The intraclass correlations for the two lesion size measurements were 0.647 (95% CI: 0.541, 0.753) and 0.554 (95% CI: 0.431, 0.677).
analysis. Most mutations were only present in approximately 10% of patients, limiting the number of patients with any given genotype to approximately five to 10 patients. Therefore, we instead compared specific subpopulations of patients to examine specific genotype-phenotype associations based on specific genes of interest identified in previous work (19) . Multiple test-correction was performed by using the Benjamini-Hochberg correction implemented in Matlab (20) .
In addition, copy number data were used to identify a subgroup of patients with high-level EGFR amplification, with high-level PDGFRA amplification, with homozygous deletions of CDKN2A, and with deletions of NF1 by using data obtained from the cBio Cancer Genomics Portal (21) . For copy number analysis, raw data were first converted into an ordinal ranking (homozygous deletion, heterozygous deletion, wild type, low-level amplification, high-level amplification) as described in the cBio Cancer Genomics Portal prior to correlation analysis. Copy number data were subsequently analyzed for associations/enrichment of radiology imaging features and copy number status of specific genes. Multiple test-correction was performed by using the Benjamini-Hochberg correction implemented in Matlab (20) . major axis and the proportion of contrast-enhanced tumor were still both significantly associated with poor survival (hazard ratio: 1.02, P = .030, and hazard ratio: 7.75, P = .037, respectively). The likelihood ratio test of the model of overall survival versus KPS alone in comparison with the model of overall survival versus KPS, length of the lesion's major axis, and proportion of contrast-enhanced tumor also indicated the significant association between overall survival and these imaging features even after adjustment for KPS (P = .0208).
Neuroimaging Features and Molecular Subtype
We found a significant association between contrast-enhanced tumor and Verhaak gene expression classification (P = .02) ( Table 2 ). In particular, the proneural expression class was enriched with GBMs that displayed low levels (, 5%) of contrast enhancement, whereas very few of the other three classes of GBM showed low levels (eg, , 5%) of contrast enhancement. There was also a significant association between nonenhanced tumor and expression class (P , .01). Similarly, the mesenchymal subtype was noted to have significantly lower rates of nonenhanced tissue compared with other tumor subtypes (P , .01).
Neuroimaging Features and Mutation Status
We did not detect any significant associations between gene mutation status and specific imaging features, likely due to the relatively heterogenous nature of mutations in GBM and the small percentage of tumors having a mutation in any individual gene (Table 3 ).
We also found that EGFR mutant GBMs (10 of 49 patients with imaging data) were significantly larger based on the T2-weighted FLAIR images than wild-type EGFR GBMs (P , .05). TP53 mutant GBMs (nine of 49 patients) were smaller than those that were wild type (P , .006) based on the T2weighted FLAIR images. EGFR mutant GBMs (n = 10) were significantly larger than TP53 mutants (n = 9; P , .0005).
Neuroimaging Features and Copy Number Expression
Our analysis indicated that there were weak correlations between imaging features and copy number variation (Table 4 ). There was only weak association between CDKN2A deletion and necrosis (P = .05 uncorrected), and amplification of EGFR and increased percentage of contrast enhancement (P = NEURORADIOLOGY: MR Imaging Predictors of Molecular Profile and Survival Gutman et al .06 uncorrected), and none after false discovery rate correction.
Discussion
Consistent with previous studies (7, 8, 22, 23) , we detected a significant correlation between overall survival and the degree of contrast enhancement as well as the length of the major axis of the lesion. Of importance, we also noted that these imaging features were still strongly associated with overall survival even after adjusting for KPS, suggesting that these radiologist-made measurements of tumor size and composition may provide additional prognostic value on top of standard clinical variables. Currently, analyses comparing the abilities of these same imaging features in addition to standard clinical variables to predict overall survival to those of standard clinical variables are underway. While data are still being generated from additional cases, the initial findings connecting radiology, outcome, and genomics clearly demonstrate the power NEURORADIOLOGY: MR Imaging Predictors of Molecular Profile and Survival Gutman et al of this approach; of importance, we demonstrated that noninvasive, imaging-based features can be used as prognostic biomarkers. The use of clinical and imaging features either alone or in conjunction with each other for prognosis is of course not a new area of research. Clinical characteristics that have emerged from recursive partitioning analysis and serve as the reference standard for predictive models in GBM include KPS, sex, and age (24) . Our Cox regression analyses found contrast enhancement to be predictive of survival, consistent with earlier studies (8, 23) . Of note, however, in many earlier studies the estimations of contrast enhancement were not based on a standardized visual feature set, which suggests that our findings may be more robust.
Value of these data also lies with the integration and correlation of imaging features with the molecular data from this TCGA cohort. We observed that tumors classified as proneural demonstrated significantly less contrast enhancement than other tumor types. Similarly, the mesenchymal subtype was noted to show consistently less nonenhancement than the other tumor subtypes. These results likely imply distinct growth properties of proneural and mesenchymal GBMs. Furthermore, tumors harboring EGFR mutations were significantly larger than EGFR wild-type tumors and TP53 mutant GBMs were significantly smaller than TP53 wild-type tumors. As a group, EGFR mutant GBMs were larger than TP53 mutant tumors. We also found that EGFR copy number amplification was marginally correlated with both contrast-enhanced tumor volume and necrosis was correlated with deletion of CDKN2A. While PIK3R1 was noted to have an association, the number of total events is so low that it is not informative. Although a number of correlations between genes that are frequently mutated in GBM and neuroimaging properties were noted, we caution that these associations must be considered preliminary due to the relatively small number of cases and also because none of these survived comparison for multiple corrections.
Other studies have attempted to develop radiogenomic phenotypes in gliomas. For example, Diehn et al (25) found that the imaging feature of mass effect (resulting from growing tumor pressing against other areas of the brain) was highly correlated to the genetic expression of genes involved in proliferation and cell-cycle progression. Likewise, similar methods were used to identify genes involved in blood-brain barrier maintenance, hypoxia, angiogenesis, and extracellular matrix remodeling owing to their upregulation in tumors with high contrast enhancement tumors compared with tumors with low contrast enhancement (5, 26) A recent study by Zinn et al (9) used volumetric measurements of the TCGA data to demonstrate specific gene associations with edema volumes.
While our study represents a methodologic and radiogenomic advance, it has a number of limitations. First, we noted a relatively heterogeneous nature of gene-level mutations, such that only a small percentage of GBMs had mutations in a given gene. With greater numbers of cases for future studies, other genotype-phenotype correlations may be uncovered. Additionally, although necrosis has been previously shown to be associated with poorer outcome (7, 8, 27) , it was not found to be a significant predictor in this study. It is possible that the percentage cutoffs used to define the groupings (eg, 0%-5%, 5%-33%) may not have been sensitive enough to detect this association. Similarly, we were unable to find a previously demonstrated association (5) between nonenhanced tumor and survival, an association Pope et al discovered by using univariable analyses. Also as discussed above, the observed correlations between copy number and mutation status did not survive comparison for multiple comparisons.
Collection and assessment of new GBM cases is still ongoing by our consortium, and with the relatively limited number of cases (n = 75) and number of features in the full visual feature set (n = 30), this initial study attempted to validate and assess whether the cardinal imaging features would be easily comparable to previous work (eg, proportion of necrosis, contrast enhancement, edema, nonenhanced tumor). This study only utilized a subset of the entire visual feature set, focusing on the semiquantitative assessments of the tumor compartments, and so does not address the reliability or reproducibility of the other features. Future work will include not only more quantitative assessments of tumor compartments by using volumetrics, but will also include metrics obtained from additional imaging modalities such as diffusion tensor and perfusion imaging.
For neuroimaging-based investigation, it is often challenging to extract objective information for scientific analysis from prose statements of imaging features by neuroradiologists who typically use idiosyncratic vocabulary. The results of our interrater assessment suggest that use of a consistent or controlled set of imaging features can substantially address concerns regarding validation and reproducibility of imaging-centric correlative research. These radiogenomic results support the theme that the phenotypic properties of a brain tumor visualized at MR imaging has the power to provide insight into the genetic and molecular properties of the tumors. These associations have important implications and could eventually assist neuroradiologists in subtyping tumors based on imaging phenotype. Moreover, what is yet to be determined is if consideration of tumor-specific imaging features can be successfully mobilized to more effectively guide therapeutic decisions for individual patients. 
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